Fly News Breaks for March 4, 2020
Mar 4, 2020 | 08:49 EDT
Wells Fargo analyst Jim Birchenough raised the firm's price target on Gilead (GILD) to $87 from $81 and keeps an Overweight rating on the shares following recent outperformance and on assessment of potential remdesivir opportunity in addressing current coronavirus outbreak. Overall, the analyst believes incremental value can be justified, and see further upside potential on broader pipeline progress, new opportunity with Forty Seven (FTSV) acquisition and potential for additional deals.
News For GILD;FTSV From the Last 2 Days
Oct 25, 2021 | 08:09 EDT
Aadi Bioscience (AADI) announced the appointment of Loretta Itri, M.D., FACP, to the role of Chief Medical Officer, CMO. Most recently, Dr. Itri was Chief Medical Officer at Immunomedics, where she oversaw the development program and approval of TRODELVY, the first TROP-2 directed antibody-drug conjugate for the treatment of unresectable locally advanced or metastatic triple-negative breast and urothelial cancers. Immunomedics was subsequently acquired by Gilead Sciences (GILD).